Dr. Ethan Morgan is a Neuroscience & Peptide Research Specialist and medical author for Neuro Peptides. He has more than 10 years of experience in scientific research, medical education, and evidence-based content focused on: Neuroscience and brain health Peptide research Neurobiology Cellular signaling and molecular research Educational Background Dr. Morgan received formal training in biomedical sciences and neuroscience, with a focus on molecular biology, cellular signaling, and research-based approaches to understanding neurological processes. For more than 10 years, he has worked with scientific literature and medical research, translating complex findings into clear and accessible educational content. His work focuses on helping readers understand emerging research involving peptides, cellular pathways, neurobiology, and related areas of biomedical science. Research Focus Areas Dr. Morgan’s primary research interests include neuroscience, peptide biology, cellular communication, and molecular mechanisms involved in neurological and physiological processes. His work involves reviewing scientific literature on research peptides and examining how specific peptides are being investigated in preclinical and clinical research. He focuses on presenting established findings separately from emerging or preliminary evidence. He does not promote the use of unapproved medicines or research peptides in humans. His content is intended for educational and research purposes only. Approach to Scientific Education Dr. Morgan believes that scientific information should be accurate, understandable, and supported by credible research. His approach is to break down complex studies and explain important findings in straightforward language without overstating what the available evidence shows. Through his writing for Neuro Peptides, he aims to help readers better understand peptide research, neuroscience, molecular biology, and emerging developments in biomedical science.
A Peptide Certificate of Analysis (COA) is a document that reports analytical testing performed on a specific peptide sample or batch. For researchers, a COA can provide important information about the material being evaluated, including its identity, reported purity, batch or lot number, analytical methods, testing date, and laboratory information. According to the FDA’s ICH […]
Research peptides are laboratory materials intended only for scientific research, while compounded peptides are drug preparations made by licensed pharmacies for patient-specific or clinical use under applicable U.S. compounding laws. Even when both products contain the same peptide sequence, their intended purpose, regulatory status, manufacturing standards, testing requirements, sterility expectations, labeling, and oversight can be […]
The FDA issued warning letters to multiple companies in 2026 after reviewing their websites, inspecting facilities, or identifying other regulatory violations involving peptide-related and drug products. In the cited cases, the FDA identified website claims, product presentation, intended use, manufacturing practices, or other regulatory issues that supported its findings. This article highlights 14 companies that […]
Recent FDA warning letters to peptide companies in 2026 show that products marketed as ‘research use only’ can attract regulatory scrutiny when their labeling, websites, or other marketing materials indicate an intended use in humans. These cases also show that FDA may consider product claims, website content, intended use, and the presentation of injectable products […]
As of September 2026, retatrutide does not have an official commercial release date. Eli Lilly is still developing the drug, although the program has advanced substantially through Phase 3 clinical trials. Retatrutide, also known as LY3437943, remains an investigational medicine developed by Eli Lilly. It is a triple receptor agonist that targets: This combination distinguishes […]
Retatrutide (LY3437943), developed by Eli Lilly and Company, is an investigational peptide currently not approved for human consumption and is under investigation. It works by targeting three hormone receptors: This unique triple-action mechanism makes it different from the rest of the peptides that have been developed for the treatment of various metabolic disorders. There have […]
